Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating and
financial results for the first quarter ended March 31, 2016.
The Company reported revenue of $12.3 million compared to $8.3
million for the comparable period in 2015, and net loss per share
of $0.05 for both periods.
“The Company reported another solid quarter of
top line growth, with the primary driver of that growth coming once
again from an increase in product revenue,” said Robert F. Apple,
President and Chief Executive Officer of the Company. “Antares also
reported significant progress on commercial and pipeline projects
which included the approval of three additional interim dosage
strengths for OTREXUP, completion of the QST-13-003 52 week phase 3
study in testosterone deficient men and the acceptance by the U.S.
Food and Drug Administration (FDA) of an abbreviated new drug
application (ANDA) filed by our partner Teva for teriparatide, a
generic form of Forteo. The teriparatide filing represents
the fourth ANDA for which Antares is the device developer and we
believe the third potential generic product with a first to file
status using one of our devices. Finally, we continue to
prepare for the mid-year 2016 launch of generic sumatriptan with
our distribution partner Teva.”
First Quarter 2016 and Recent
Highlights
- Completed the 52 week QuickShot® phase 3 study in testosterone
deficient men, and announced positive final pharmacokinetic and
safety data. The Company anticipates that the last patient in
the ongoing 26 week supplemental safety study should receive their
final treatment soon. These two studies will form the basis
for a New Drug Application for QS T which we plan to submit to the
FDA at the end of this year or early in 2017.
- Announced the approval by the U.S. FDA of three new dosage
strengths of OTREXUP™ (methotrexate) injection. The new
dosage strengths of 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4
ml will complement the five already approved and marketed
strengths.
- Disclosed that the “Pen 1” development project with Teva
Pharmaceuticals Industries, Ltd. (Teva) relates to a generic form
of Forteo® (teriparatide [DNA origin] injection), which is an
injectable treatment for osteoporosis in postmenopausal women and
men at high risk for fracture and for glucocorticoid induced
osteoporosis in men and postmenopausal women.
- Delivered $6.0 million in pre-launch epinephrine devices to
Teva in the first quarter.
- Appointed Robert F. Apple to the position of President and
Chief Executive Officer and a member of the Antares Board of
Directors. Mr. Apple most recently served as the
Company’s Executive Vice President and Chief Operating
Officer.
First Quarter Financial
Results
Total revenue was $12.3 million for the three
months ended March 31, 2016, compared to $8.3 million for the
comparable period in 2015, representing growth in total revenue of
48%. See Table 1 attached for further details on
revenues.
Product sales represent sales of our proprietary
products and devices or device components to our partners.
Product sales were $10.8 million for the three months ended March
31, 2016, compared to $4.6 million for the comparable period in
2015. The increase in product sales was primarily driven by
the sale of $6 million in pre-launch quantities of the epinephrine
auto injector to Teva and by increased sales of OTREXUP™.
The Company expects to complete shipment of pre-launch
epinephrine auto injector devices in the second quarter of
2016.
Development revenues represent amounts earned
under arrangements with partners in which we develop new products
on their behalf. Frequently, we receive payments from our
partners that are initially deferred and recognized as revenue over
a development period or upon completion of defined
deliverables. Development revenue was $1.1 million for the
three months ended March 31, 2016, compared to $2.4 million for the
comparable period in 2015. The decrease in development
revenue is related to the completion of certain deliverables and
development activities for the epinephrine auto injector, which
accounted for substantially all of the development revenue in the
first quarter of 2015. The decrease was partially offset by
additional development activities for the AMAG auto injector in
2016.
Licensing revenues represent the amounts
recognized from up-front or milestone payments received from
partners that are initially deferred and recognized over the life
of our agreements. Licensing revenue was $51 thousand for the
three months ended March 31, 2016, compared to $0.9 million for the
comparable period in 2015. The decrease in licensing revenue
is related to a promotion and license agreement with LEO Pharma,
Inc., which was terminated on June 23, 2015.
Royalty revenue is recognized primarily from the
in-market sales of products sold by our partners. Royalty
revenue was $0.3 million for the three months ended March 31, 2016,
compared to $0.5 million for the comparable period in 2015.
Total gross profit increased in the first
quarter of 2016 to $5.5 million compared to $4.7 million in the
same period in 2015. The increase was primarily driven by sales of
pre-launch quantities of the epinephrine auto injector to Teva and
an increase in OTREXUP™ sales.
Total operating expenses were approximately
$13.3 million for the first quarter of 2016 compared to $11.4
million in the comparable period of 2015. The increase in
operating expenses in the first quarter of 2016 was primarily
driven by external expenses incurred in connection with the
development of QuickShot testosterone and increased personnel
costs.
Net loss was approximately $7.7 million for the
first quarter of 2016, compared to $6.8 million in the comparable
period in 2015. Net loss per share was $0.05 for the quarters
ended March 31, 2016 and 2015.
At March 31, 2016, cash and investments totalled
approximately $42.1 million compared to approximately $47.9 million
at December 31, 2015.
Conference Call, Call Replay and
Webcast
Antares executives will provide a Company update
and review first quarter 2016 financial results via webcast and
conference call on Monday, May 9, 2016, at 8:30 a.m. ET (Eastern
Time). The webcast of the conference call, which will include a
slide presentation, can be accessed through the link
located on the “ATRS Investor Information” section of the
Company’s website (www.antarespharma.com) under the “Webcast”
tab. Alternatively, callers may participate in the audio
portion of the conference call by dialing 1-888-471-3843 (US), or
1-719-325-2244 (International). Callers should reference the
Antares Pharma conference call or conference identification code
1348142. Callers can access the slide presentation on the “ATRS
Investor Information” section of the Company’s website under the
“Presentations” tab. Webcast and telephone replays of the
conference call will be available from 11:30 a.m. ET on Monday, May
9, 2016, through 11:30 a.m. ET on Tuesday, May 24, 2016. To access
the replay, callers should dial 1-888-203-1112 (US) or
1-719-457-0820 (International) and enter passcode
1348142.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. Antares
Pharma is also developing QuickShot® Testosterone for testosterone
replacement therapy, and has recently received a therapeutically
equivalent approval from the U.S. Food and Drug Administration for
VIBEX® Sumatriptan USP for the acute treatment of migraines.
The Company's technology platforms include VIBEX® disposable auto
injectors, disposable multi-use pen injectors and reusable
needle-free injectors. Antares Pharma has a multi-product deal with
Teva Pharmaceutical Industries, Ltd. that includes VIBEX®
epinephrine, exenatide multi-dose pen, and teriparatide multi-dose
pen. Our reusable needle-free injector for use with human
growth hormone (hGH) is sold worldwide by Ferring B.V. The
Company is also working with AMAG Pharmaceuticals on a subcutaneous
method of administering Makena, a progesterone product indicated
for use in lowering the risk of pre-term birth.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the timing and results
of the phase 3 studies for QuickShot® Testosterone (QS T) and
acceptance of the data by the U.S. Food and Drug Administration
(“FDA”); the Company’s ability to successfully complete a New Drug
Application (“NDA”) for QS T and submit to the FDA and approval of
the same by the FDA; Teva’s ability to adequately and timely
respond to the Complete Response Letter received from the FDA for
the VIBEX® epinephrine pen Abbreviated New Drug Application
(“ANDA”) and approval by the FDA of the same, the timing and
therapeutic equivalence rating thereof, and any future purchase
orders and revenue pre or post FDA approval; the timing of the
launch of VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; the outcome of the pending patent litigation
between Teva Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly
and Company regarding the Teriparatide multi-dose pen; the timing
and approval, if any, by the FDA of Teva’s ANDA for the
Teriparatide multi-dose pen and any future revenue resulting
therefrom; the outcome of the pending patent litigation between
Teva and AstraZeneca regarding the Exenatide multi-dose pen;
FDA action with respect to Teva’s ANDA filed for the Exenatide pen
and future revenue from the same; continued growth of prescriptions
and sales of OTREXUP™; the timing and results of the
development project with AMAG Pharmaceuticals for an auto injector
for Makena; the timing and results of research projects, clinical
trials, and product candidates in development; actions by the
FDA or other regulatory agencies with the respect to the Company’s
products or product candidates of its partners; continued growth in
product, development, licensing and royalty revenue; the Company’s
ability to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2015, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
TABLES FOLLOW
ANTARES PHARMA, INC. |
|
Table 1 - CONSOLIDATED REVENUE
DETAILS |
|
(amounts in thousands, except for
percentages) |
|
(unaudited) |
|
|
|
|
|
Three Months Ended March 31, |
|
|
Increase |
|
|
|
2016 |
|
|
2015 |
|
|
(Decrease) |
|
OTREXUP™ |
|
$ |
3,310 |
|
|
$ |
3,004 |
|
|
|
|
10 |
% |
|
Needle-free injector
devices and components |
|
|
1,552 |
|
|
|
1,421 |
|
|
|
|
9 |
% |
|
Auto injector and pen
injector devices |
|
|
5,979 |
|
|
|
198 |
|
|
|
|
2919 |
% |
|
Total product sales |
|
|
10,841 |
|
|
|
4,623 |
|
|
|
|
134 |
% |
|
Development revenue |
|
|
1,098 |
|
|
|
2,388 |
|
|
|
|
-54 |
% |
|
Licensing revenue |
|
|
51 |
|
|
|
883 |
|
|
|
|
-94 |
% |
|
Royalties |
|
|
329 |
|
|
|
453 |
|
|
|
|
-28 |
% |
|
Total revenue |
|
$ |
12,319 |
|
|
$ |
8,348 |
|
|
|
|
48 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANTARES PHARMA, INC. |
|
Table 2 - CONSOLIDATED CONDENSED STATEMENTS OF
OPERATIONS |
|
(amounts in thousands except per share
amounts) |
|
(unaudited) |
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2016 |
|
|
2015 |
|
Revenue: |
|
|
|
|
|
|
|
|
Product sales |
|
$ |
10,841 |
|
|
$ |
4,623 |
|
Development revenue |
|
|
1,098 |
|
|
|
2,388 |
|
Licensing revenue |
|
|
51 |
|
|
|
883 |
|
Royalties |
|
|
329 |
|
|
|
453 |
|
Total revenue |
|
|
12,319 |
|
|
|
8,348 |
|
Cost of revenue |
|
|
6,776 |
|
|
|
3,675 |
|
Gross profit |
|
|
5,543 |
|
|
|
4,673 |
|
Research and
development |
|
|
5,648 |
|
|
|
4,378 |
|
Selling, general and
administrative |
|
|
7,603 |
|
|
|
7,037 |
|
Total operating expenses |
|
|
13,251 |
|
|
|
11,415 |
|
Operating loss |
|
|
(7,708 |
) |
|
|
(6,742 |
) |
Other income
(expense) |
|
|
52 |
|
|
|
(46 |
) |
Net loss |
|
$ |
(7,656 |
) |
|
$ |
(6,788 |
) |
Basic and diluted net loss
per common share |
|
$ |
(0.05 |
) |
|
$ |
(0.05 |
) |
Basic and diluted weighted
average common shares outstanding |
|
|
154,858 |
|
|
|
131,745 |
|
|
|
|
|
|
|
|
|
|
ANTARES PHARMA, INC. |
|
Table 3 – CONSOLIDATED CONDENSED BALANCE
SHEETS |
|
(amounts in thousands) |
|
(unaudited) |
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2016 |
|
|
2015 |
|
ASSETS |
|
|
|
|
|
|
|
|
Cash and investments |
|
$ |
42,111 |
|
|
$ |
47,911 |
|
Accounts receivable |
|
|
7,977 |
|
|
|
7,952 |
|
Inventories |
|
|
5,270 |
|
|
|
5,724 |
|
Equipment, molds,
furniture and fixtures, net |
|
|
17,143 |
|
|
|
14,793 |
|
Patent rights, net |
|
|
2,331 |
|
|
|
2,435 |
|
Goodwill |
|
|
1,095 |
|
|
|
1,095 |
|
Other assets |
|
|
5,381 |
|
|
|
4,652 |
|
Total Assets |
|
$ |
81,309 |
|
|
$ |
84,562 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders’
Equity |
|
|
|
|
|
|
|
|
Accounts payable and
accrued expenses |
|
$ |
15,491 |
|
|
$ |
11,675 |
|
Deferred revenue |
|
|
5,935 |
|
|
|
5,844 |
|
Stockholders’ equity |
|
|
59,883 |
|
|
|
67,043 |
|
Total Liabilities and Stockholders’
Equity |
|
$ |
81,309 |
|
|
$ |
84,562 |
|
|
|
|
|
|
|
|
|
|
Contacts:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024